Crossmark

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Crossref DOI link: https://doi.org/10.1007/s40268-018-0247-7

Published Online: 2018-09-19

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lashari, Bilal H. https://orcid.org/0000-0001-8257-7740
Vallatharasu, Yazhini

Kolandra, Lakshmi

Hamid, Mohsin

Uprety, Dipesh
License Information

Text and Data Mining valid from 2018-09-19
More Information

Article History

First Online: 19 September 2018

Compliance with Ethical Standards

:

: Bilal H. Lashari has no conflict of interest. Yazhini Vallatharasu has no conflict of interest. Lakshmi Kolandra has no conflict of interest. Mohsin Hamid has no conflict of interest. Dipesh Uprety has no conflict of interest.

: No funding, institutional, personal or commercial, was received by the authors regarding the preparation of this article.